Mandate

Vinge advises CMA Microdialysis in connection with the sale of pre-clinical business

July 04, 2011

Vinge has advised CMA Microdialysis in connection with the sale of its pre-clinical business to Harvard Biosciences. The main shareholders of MCA Microdialysis are Investor Growth Capital and Bure Equity. In connection with the transaction, the company has changed its name to Dipylon Medical.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, fellow partner Fredrik Dahl and associate Claes Henriksson.

Related

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025

Vinge advises FAM AB on the acquisition of Aktiebolaget Näckström

Vinge has advised FAM AB on its acquisition of Aktiebolaget Näckström from Vectura Fastigheter AB. The principal assets of Aktiebolaget Näckström comprise the property Stockholm Näckström 6 (Arsenalsgatan 8) and Villa Täcka udden.
October 16, 2025

Vinge has advised FAM in connection with its investment in GreenIron

Vinge has advised FAM AB, owned by the Wallenberg Foundations, in connection with its investment in GreenIron H2 AB. Through the round, GreenIron raised in total SEK 125 million in additional funding from existing shareholders, with FAM now becoming the company’s largest owner.
October 16, 2025